Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.
Non-Hodgkin's Lymphoma|Lymphoma, Diffuse|Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic
DRUG: veltuzumab
Safety of hA20 with this administration schedule and dosing, first 12 weeks, then over 2 years|tolerance of hA20 with this administration schedule and dosing, first 12 weeks|immunogenicity of hA20 with this administration schedule and dosing, first 12 weeks, as needed over 2 years
Pharmacodynamics of hA20, first 12 weeks, then up to 2 years|pharmacokinetics hA20, first 12 weeks, then up to 2 years|assess efficacy, 4 and 12 weeks, then every 3 months for 2 years
This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.